| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant therapy in renal cell carcinoma
|
Massari, Francesco
|
|
2017
|
60 |
C |
p. 152-157
6 p.
|
artikel
|
| 2 |
CDK4/6 inhibition in early and metastatic breast cancer: A review
|
de Groot, A.F.
|
|
2017
|
60 |
C |
p. 130-138
9 p.
|
artikel
|
| 3 |
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
|
Miglietta, F.
|
|
2017
|
60 |
C |
p. 100-108
9 p.
|
artikel
|
| 4 |
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
|
Carrassa, Laura
|
|
2017
|
60 |
C |
p. 139-151
13 p.
|
artikel
|
| 5 |
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials
|
Gyawali, Bishal
|
|
2017
|
60 |
C |
p. 18-23
6 p.
|
artikel
|
| 6 |
Editorial Board
|
|
|
2017
|
60 |
C |
p. IFC-
1 p.
|
artikel
|
| 7 |
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis
|
Goldvaser, Hadar
|
|
2017
|
60 |
C |
p. 53-59
7 p.
|
artikel
|
| 8 |
Erratum to ‘Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies’ [Cancer Treat. Rev. 58C (2017) 22–33]
|
Park, Jeong A
|
|
2017
|
60 |
C |
p. 158-
1 p.
|
artikel
|
| 9 |
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035)
|
Tartari, Francesca
|
|
2017
|
60 |
C |
p. 12-17
6 p.
|
artikel
|
| 10 |
IGF system targeted therapy: Therapeutic opportunities for ovarian cancer
|
Liefers-Visser, J.A.L.
|
|
2017
|
60 |
C |
p. 90-99
10 p.
|
artikel
|
| 11 |
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
|
Heppt, Markus V.
|
|
2017
|
60 |
C |
p. 44-52
9 p.
|
artikel
|
| 12 |
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
|
Ferrara, Roberto
|
|
2017
|
60 |
C |
p. 60-68
9 p.
|
artikel
|
| 13 |
Interleukin-8 in cancer pathogenesis, treatment and follow-up
|
Alfaro, Carlos
|
|
2017
|
60 |
C |
p. 24-31
8 p.
|
artikel
|
| 14 |
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
|
Chiaravalli, Marta
|
|
2017
|
60 |
C |
p. 32-43
12 p.
|
artikel
|
| 15 |
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
|
Broccoli, Alessandro
|
|
2017
|
60 |
C |
p. 120-129
10 p.
|
artikel
|
| 16 |
Systemic treatment of renal cell cancer: A comprehensive review
|
Sánchez-Gastaldo, Amparo
|
|
2017
|
60 |
C |
p. 77-89
13 p.
|
artikel
|
| 17 |
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
|
Strickler, John H.
|
|
2017
|
60 |
C |
p. 109-119
11 p.
|
artikel
|
| 18 |
The Notch-3 receptor: A molecular switch to tumorigenesis?
|
Inder, Shakeel
|
|
2017
|
60 |
C |
p. 69-76
8 p.
|
artikel
|
| 19 |
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target
|
Pilotto, S.
|
|
2017
|
60 |
C |
p. 1-11
11 p.
|
artikel
|
Tijdschrift beschrijving